Ablynx

#	Item
41	ABLYNX ANNOUNCES WORLDWIDE CANCER IMMUNOTHERAPY DISCOVERY COLLABORATION AND LICENSING AGREEMENT WITH MERCK Utilising the Nanobody® technology to generate multi-specific drugs GHENT, Belgium, February 3, 2014 –Ablynx [ Add to Reading List Source URL: hugin.info Language: English - Date: 2014-02-02 12:55:18 Vrije Universiteit Brussel Immune system Immunotherapy Merck & Co. Single-domain antibody Serono Pharmaceutical industry Cancer immunotherapy Medicine Immunology Ablynx
42	ABLYNX’S ANTI-vWF NANOBODY, CAPLACIZUMAB, ACHIEVES CLINICAL PROOF-OF-CONCEPT IN PHASE II TITAN STUDY    Add to Reading List Source URL: www.ablynx.com Language: English - Date: 2014-06-17 00:50:34 Coagulation system Clinical research Pharmacology Bioethics Medical ethics Thrombotic thrombocytopenic purpura Platelet Thrombocytopenia Von Willebrand disease Medicine Blood Biology
43	© Bayer © VIB Add to Reading List Source URL: sectie.ewi-vlaanderen.be Language: English - Date: 2010-09-14 04:24:43 Ablynx Technology Ghent CropDesign Single-domain antibody Bayer FlandersBio Politics of Belgium Belgium Vrije Universiteit Brussel
44	PDF Document Add to Reading List Source URL: www.vub.ac.be Language: English - Date: 2010-07-05 16:34:38 Flanders Europe Science and technology in Belgium Vrije Erasmushogeschool Brussel Université libre de Bruxelles Free University of Brussels University spin-off Ablynx Vrije Universiteit Brussel Universities in Belgium Belgium